Literature DB >> 22002567

Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008.

Lotte Holm Land1, Susanne Oksbjerg Dalton, Maj-Britt Jensen, Marianne Ewertz.   

Abstract

The incidence of breast cancer, as well as other chronic disease, increases with age, older breast cancer patients being more likely than younger to suffer from other diseases at time of diagnosis. Our objective was to assess the effect of comorbidity on mortality after early breast cancer. 62,591 women diagnosed with early breast cancer 1990-2008 were identified using the Danish Breast Cancer Cooperative Group Registry. Data were linked to the Danish National Patient Register and the Danish Register of Causes of Death. Main outcome measures were mortality from all causes, breast cancer, and non-breast cancer causes in relation to Charlson comorbidity index (CCI). Compared with patients without comorbidity (CCI 0), the presence of comorbidity increased the risk of dying from breast cancer as well as other causes with adjusted hazard ratios (HRs) for all-cause mortality of 1.45 (CI 95% 1.40-1.51) for CCI 1, 1.52 (95% CI 1.45-1.60) for CCI 2, and 2.21 (95% CI 2.08-2.35) for CCI 3+. Equivalent HRs for breast cancer-specific mortality were 1.30 (95% CI, 1.24-1.36) for CCI 1, 1.31 (95% CI 1.23-1.39) for CCI 2, and 1.79 (95% CI, 1.66-1.93) for CCI 3+ (all P values < 0.0001). For patients with CCI 0, 5-year overall survival increased over time from 72.5% (95% CI, 71.7-73.3%) in 1990-1994 to 81.6% (95% CI, 80.9-82.2) in 2000-2004, whereas the 5-year overall survival remained stable around 43% among the patients with CCI 3+. This population-based cohort study shows that compared with patients without comorbidity, the risk of dying from breast cancer as well as other causes increased significantly with increasing CCI score. While survival improved over time for patients without comorbidity, no improvement was seen among patients with severe comorbidity (CCI 3+).

Entities:  

Mesh:

Year:  2011        PMID: 22002567     DOI: 10.1007/s10549-011-1819-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  34 in total

Review 1.  Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations.

Authors:  Paige Green McDonald; Mary O'Connell; Susan K Lutgendorf
Journal:  Brain Behav Immun       Date:  2013-01-16       Impact factor: 7.217

2.  Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study.

Authors:  Anna Z de Boer; Heleen C van der Hulst; Nienke A de Glas; Perla J Marang-van de Mheen; Sabine Siesling; Linda de Munck; Kelly M de Ligt; Johanneke E A Portielje; Esther Bastiaannet; Gerrit Jan Liefers
Journal:  Oncologist       Date:  2019-09-12

3.  Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC).

Authors:  Anna H Wu; Allison W Kurian; Marilyn L Kwan; Esther M John; Yani Lu; Theresa H M Keegan; Scarlett Lin Gomez; Iona Cheng; Salma Shariff-Marco; Bette J Caan; Valerie S Lee; Jane Sullivan-Halley; Chiu-Chen Tseng; Leslie Bernstein; Richard Sposto; Cheryl Vigen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-25       Impact factor: 4.254

4.  Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.

Authors:  Dirk Müller; Marion Danner; Kerstin Rhiem; Björn Stollenwerk; Christoph Engel; Linda Rasche; Lisa Borsi; Rita Schmutzler; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2017-04-05

5.  Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer.

Authors:  Marloes G M Derks; Cornelis J H van de Velde; Daniele Giardiello; Caroline Seynaeve; Hein Putter; Johan W R Nortier; Luc Y Dirix; Esther Bastiaannet; Johanneke E A Portielje; Gerrit-Jan Liefers
Journal:  Oncologist       Date:  2019-01-03

6.  Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?

Authors:  Dejana Braithwaite; Weiwei Zhu; Rebecca A Hubbard; Ellen S O'Meara; Diana L Miglioretti; Berta Geller; Kim Dittus; Dan Moore; Karen J Wernli; Jeanne Mandelblatt; Karla Kerlikowske
Journal:  J Natl Cancer Inst       Date:  2013-02-05       Impact factor: 13.506

7.  Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study.

Authors:  Sarah Nechuta; Wei Lu; Ying Zheng; Hui Cai; Ping-Ping Bao; Kai Gu; Wei Zheng; Xiao Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2013-04-19       Impact factor: 4.872

Review 8.  Building a Cardio-Onco-Hematology Program.

Authors:  Joerg Herrmann; Charles Loprinzi; Kathryn Ruddy
Journal:  Curr Oncol Rep       Date:  2018-09-10       Impact factor: 5.075

9.  Prognostic Importance of Comorbidity and the Association Between Comorbidity and p16 in Oropharyngeal Squamous Cell Carcinoma.

Authors:  S Andrew Skillington; Dorina Kallogjeri; James S Lewis; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

10.  Influence of comorbidity on cancer patients' rehabilitation needs, participation in rehabilitation activities and unmet needs: a population-based cohort study.

Authors:  Lise Vilstrup Holm; Dorte Gilså Hansen; Jakob Kragstrup; Christoffer Johansen; Rene dePont Christensen; Peter Vedsted; Jens Søndergaard
Journal:  Support Care Cancer       Date:  2014-03-19       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.